Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 2 examiners • 0 of 3 (0%) have an AI response strategy ready
Creative Bio-Peptides Inc. has 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are handled by 2 distinct examiners across 2 distinct art units, indicating some level of concentration within the portfolio. The busiest examiner, ORWIG, KEVIN S, is responsible for 2 pending office actions.
With 2 pending office actions assigned to ORWIG, KEVIN S, this examiner has a significant influence on the company's current prosecution success. The other pending office action is handled by the other distinct examiner. The presence of 2 distinct art units suggests that the 3 pending office actions are technically related enough to be grouped, but distinct enough to span different administrative units.
Practitioners can focus on the preferences of the busiest examiner to resolve 2 of the 3 pending matters. This concentration allows for a more streamlined strategy compared to a portfolio where every action is with a different examiner. The 3 pending office actions within the Biotechnology & Pharmaceuticals field represent a focused effort that relies heavily on the interactions within these 2 distinct art units. This structure provides a balance between technical diversity and administrative concentration.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (33%) |
| Double-patenting + other | 1 (33%) |
| Multi-statute (no §101) | 1 (33%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| ORWIG, KEVIN S | 2 | 25.5% | +40.1% |
| BANERJEE, KOYELI | 1 | 33.3% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19213362 | Use of an All-D-Pentapeptide Chemokine Antagonist to Reduce Opioid Dose in a Person with Pain | ORWIG, KEVIN S | — |
| 18560768 | Compositions and Methods for Treating Persistent Postsurgical Pain | BANERJEE, KOYELI | — |
| 17869925 | USE OF AN ALL-D-PENTAPEPTIDE CHEMOKINE ANTAGONIST TO REDUCE OPIOID DOSE IN A PERSON WITH PAIN | ORWIG, KEVIN S | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19213362 | Use of an All-D-Pentapeptide Chemokine Antagonist to Reduce Opioid Dose in a Person with Pain | ORWIG, KEVIN S | — |
| 17869925 | USE OF AN ALL-D-PENTAPEPTIDE CHEMOKINE ANTAGONIST TO REDUCE OPIOID DOSE IN A PERSON WITH PAIN | ORWIG, KEVIN S | — |
| Art Unit | Apps |
|---|---|
| 3991 | 2 |
| 1654 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19213362 | Use of an All-D-Pentapeptide Chemokine Antagonist to Reduce Opioid Dose in a Person with Pain | ORWIG, KEVIN S | 3991 | §103§112DP | Non-Final OA | — | Pending | May 20, 2025 |
| 18560768 | Compositions and Methods for Treating Persistent Postsurgical Pain | BANERJEE, KOYELI | 1654 | §103§112Other | Non-Final OA | — | Pending | Nov 14, 2023 |
| 17869925 | USE OF AN ALL-D-PENTAPEPTIDE CHEMOKINE ANTAGONIST TO REDUCE OPIOID DOSE IN A PERSON WITH PAIN | ORWIG, KEVIN S | 3991 | §103 | Final Rejection | — | Pending | Jul 21, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCreative Bio-Peptides Inc. has 3 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Kevin S Orwig has the most, with 2 of Creative Bio-Peptides Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
